Global Human Microbiome Market 2022-2028

Global Human Microbiome Market 2022-2028

The global human microbiome market is estimated to exceed $175.0 million by the end of 2021, which is further estimated to grow at a CAGR of 26.7% during the forecast period (2022-2028). Human microbiome study includes the study of microbiomes on the human body to establish a correlation between microbiomes and human health. Microbiome sequencing is one of the key processes, which is used for analyzing the human microbiomes. The development of innovative sequencing technologies such as next-generation sequencing and third-generation sequencing are purposely used to generate data on the human microbiome. Various pivotal factors that are driving the global human microbiome market includes the increasing emphasis on human microbiome research for early detection and diagnosis of diseases, increasing healthcare spending, and rising investment in R&D. As per OMR Analysis, microbiome therapeutics and diagnostics companies have garnered over $4.0 billion funding during 2014-2021. Further, the government support to boost the human microbiome research is also contributing to the market growth during the forecast period. For instance, in August 2021, European venture company Seventure Partners revealed that the French government has approved the eligibility of its Health for Life Capital II (HFL 2) fund for microbiome innovation funding. As part of the initiative, French institutional investors have committed to devote over $5.8 billion to the financing of innovative companies by December 31, 2022.

Giant biotechnology players and startups are collaborating to invest heavily in human microbiome research. For instance, in October 2021, Enterome signed a global licensing, co-development, and co-promotion agreement with Takeda. The agreement covers Enterome’s investigational drug candidate EB8018 (now called sibofimloc) in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases. Further, in November 2021, Enterome entered an Immuno-Oncology collaboration with Bristol Myers Squibb. The collaboration is focused on the discovery and development of microbiome-derived biomarkers, drug targets and bioactive molecules to be developed as potential companion diagnostics and therapeutics for cancer. Furthermore, various market players are engaging in collaborating AI with the human microbiome to promote studies on gut microbiomes. For instance, in 2021, Viome, Inc. has developed Vie, the company’s AI system, that uses data gathered from four sources including biological testing, expert knowledge, customer feedback, and scientific literature.

The global human microbiome market is segmented based on product type, disease, and technology. Based on product type, the market is segmented into probiotics, prebiotics, medical foods, drugs and therapies, and others. Among these products, the probiotics segment held the highest market share. The market for probiotics is driven by significant funding and efforts by companies for discovering therapeutics for a gastrointestinal disorder such as inflammatory bowel disease (IBD) and ulcerative colitis across the globe. For instance, in September 2021, BiomX Collaborated with Boehringer Ingelheim for Discovering Micro Biome-Based Biomarkers in IBD. This will result in the advancement of therapies and this platform combines ultra-high-resolution DNA analysis, AI techniques, and high-scale cloud computing resources to build classifiers of high sensitivity and specificity. Further, the drugs and therapies segment is growing at the highest CAGR of 28.7% during the forecast period, driven by its continuous human microbiome research in the development of drugs for the treatment of cancer, infectious disease, autoimmune disease, among others. The increasing number of drug pipelines based on the human microbiome is significantly offering growth opportunities to the market across the globe.

Based on disease, the market is segmented into cancer, gastrointestinal disorder, infectious diseases, diabetes, and others. The gastrointestinal disorder segment held the highest market share. Based on technology, the market is segmented into genomics, proteomics, and metabolomics. The genomics technology is significantly used in the human microbiome research and is anticipated to exhibit a CAGR of 27.0%, during the forecast period. The advancement in genomic and clinical science has established the advanced prospects to further customize healthcare to every patient and drive the global human microbiome market. The Center for Individualized Medicine at Mayo Clinic is practicing personalized medicine and using it to the complete spectrum of healthcare with the use of sophisticated techniques of molecular analysis and genomic sequencing. Furthermore, numerous players in the electronic industry in China are collaborating to create infrastructure for the storage of genomic data which will further aid the growth of the market in near future.

Geographically, the market is further segmented based on four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe (RoE), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and Rest of the World (RoW) (Latin America and the Middle East and Africa). Among these, the human microbiome market held the highest share in North America. The growth is attributed to the cohesive government initiatives and funding for microbiome research. North America includes the US and Canada as the major economies that are contributing to the growth of the market. The US government has invested significantly in these areas to promote the research on microbiomes and their impact on the biological processes. The US government has devised an Interagency Strategic Plan for Microbiome Research for 2021-2022 to understand the exact functioning of microbiomes in humans. Such government support and funding in the market are fueling the growth of the market in the North American region.

The key players that are contributing significantly to the growth of the global human microbiome market include Illumina Inc., Seres Therapeutics, Inc., Enterome SA, Second Genome Inc., Qiagen NV, and Thermo Fisher Scientific Inc. The companies are launching innovative products in the market, to meet the increasing demand for human microbiome in the diagnosis of diseases and the development of personalized medicine. Furthermore, the market players are adopting various strategies, to sustain in the highly competitive market, which includes merger & acquisition, geographical expansion, joint ventures, and product development, among others. For instance, in June 2021, Pendulum Therapeutics, Inc. launched Pendulum Glucose Control, the first and only medical probiotic clinically shown to lower A1C and blood sugar spikes. This step of the company towards the development of medical food for the management of type 2 diabetes through the gut microbiome with Pendulum Glucose Control, is expected to enhance the company’s position in the global human microbiome medical foods market.